Experimental procedures for the subsequent extraction of lymphatic tissues to test lymphoid dendritic cell activation are described after treatment of an immunostimulating nanomaterial.
Method Article
Experimental procedures for the subsequent extraction of lymphatic tissues to test lymphoid dendritic cell activation are described after treatment of an immunostimulating nanomaterial.
For evaluation of a new therapeutic agent for immunotherapy or vaccination, analysis of immune cell activation in lymphatic tissues is essential. Here, we investigated immunological effects of a novel lipid-DNA immunostimulant in nanoparticle form from different administration routes in the mouse: oral, intranasal, subcutaneous, footpad, intraperitoneal, and intravenous. These injections will directly influence the immune response, and harvesting lymphatic tissues and analysis of dendritic cell (DC) activation in the tissues are crucial parts of these evaluations. The extraction of mediastinal lymph nodes (mLNs) is important but quite complex because of the size and location of this organ. A stepwise procedure for harvesting the inguinal lymph node (iLN), mLN, and spleen and analyzing DC activation by flow cytometry is described.
Advances in immunology and nanomaterials have led to an abundance of potential new therapeutic strategies for applications in biomedicine, including drug delivery and immunostimulation. Optimization of the administration route is a vital aspect affecting the efficacy of immunostimulatory agents. An immunostimulatory nanoparticle (INP) consisting of DNA is a newly developed nano-immune adjuvant self-assembled by microphase separation because of the amphiphilic structure of lipid-DNA1. Therefore, protocols for INP involving administration of the material1 in vivo via different routes, and three procedures for....
Access restricted. Please log in or start a trial to view this content.
All experimental procedures including animal handling, sacrifice, and organ isolation were performed in strict accordance with the rules of the International Animal Care and Use Committee at Shanghai Public Health Clinical Center and Asan Medical Center. The study protocol was approved by the respective committees on the Ethics of Animal Experiments at Shanghai Public Health Clinical Center (Mouse Protocol Number: SYXK-2010-0098) and Asan Medical Center (2016-02-168).
1. Preparation of Material
NOTE: A nano-adjuvant, INP, comprised of a self-assembled lipid-DNA carrier, namely U4T, and CpG-motif containing oligonuc....
Access restricted. Please log in or start a trial to view this content.
To evaluate appropriate injection routes of INP for lymphatic tissue DC activation, the DC population as lineage was defined as -CD11c+ cells in the spleen, iLN, and mLN and analyzed the expression levels of co-stimulatory molecules. Treatment of INP by subcutaneous (s.c.) and intravenous (i.v.) injection promoted substantial increases in CD40, CD80, and CD86 expression in the spleen and iLN DCs (Figure 2B and 2.......
Access restricted. Please log in or start a trial to view this content.
Many advances in nanotechnology and immunology have been achieved through therapeutic research of drug delivery and immunostimulation. Careful selection of the injection method is known to be important for immunostimulation, which was the focus of the present study.
Different injection routes were evaluated for a naturally non-toxic and biodegradable DNA-based material, INP (immunostimulatory nanoparticle), to determine which route yielded the best outcome. This approach is also relevant for d.......
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
This research was supported by Creative Materials Discovery Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2017M3D1A1039421) and by Marine Biotechnology Program funded by the Ministry of Oceans and Fisheries, Republic of Korea and a grant (20150220).
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| Material | |||
| phosphate buffer saline | Corning | 21-040-CVR | Washing organs |
| (PBS, pH 7.4) | |||
| isoflurane solution | Aesica Queenborough limited | 26675-46-7 | Anesthesia process |
| Tuberculin 1mL syringe - | Junglim | N/A | Injection |
| 50 mL conical tube | S.P.L | 50050 | Anesthesia process |
| 1mL Insulin Syringe | (BD Ultra-FineTMII)_short needle | 324826 | Intramuscular Injection |
| DMEM High Glucose | Hyclone | SH30081.01 | Storing organs |
| Histopaque | Sigma-Aldrich | 10771 | FACS analysis |
| Ethyl alcohol anhydrous 99.5 % | Daejung | 4022-4110 | Disinfectant |
| Equipments | |||
| FineCycler C100 (Thermocycler) | Ssufine | - | Anealing |
| Centrifuge | Centrifuge | ||
| FACS tube | FALCON | 2052 | FACS analysis |
| Automated High-performance Flow Cytometer | BD (USA), FACSVerse | - | FACS analysis |
Access restricted. Please log in or start a trial to view this content.
Request permission to reuse the text or figures of this JoVE article
Request Permission